Health
BioVaxys Files Patent Application for Novel COVID-19 Diagnostic for T-Cell Immunity – Yahoo Finance
Vancouver, British Columbia–(Newsfile Corp. – November 2, 2020) – BioVaxys Technology Corp. (CSE: BIOV) (“BioVaxys” or “the Company”), a world leader in…
Vancouver, British Columbia–(Newsfile Corp. – November 2, 2020) – BioVaxys Technology Corp. (CSE: BIOV) (“BioVaxys” or “the Company”), a world leader in haptenized protein vaccine research and development, announced today that it has filed a Provisional Patent Application with the U.S. Patent and Trademark Office entitled METHOD AND KIT FOR DETECTION OF CELL MEDIATED IMMUNE RESPONSE related to the potential development of a diagnostic for evaluating the presence or absence of a T-cell immune response…
-
Noosa News24 hours agoWhere, when and why? Everything you need to know about Sunday’s pro-Palestine protest march in Brisbane
-
General20 hours agoIndia to defend ‘red lines’ as fresh tariffs loom
-
General16 hours agoAlbanese government to freeze construction code until 2029, fast-track housing approvals
-
General22 hours agoCollingwood’s Sarah Rowe returned after just 16 days from collarbone surgery as Magpies beat GWS in AFLW